The Pharma Data

NOVEMBER 19, 2020

A study out of Rutgers University found that healthcare staffers, especially nurses, have a higher prevalence of COVID-19 than non-healthcare workers. Centers for Disease Control and Prevention (CDC), there were more than 216,000 confirmed COVID-19 cases in healthcare workers in the U.S., As of November 15, 2020, according to the U.S.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

JUNE 18, 2021

“The CLL14 trial results observed after four years of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience long-lasting responses without disease progression, years after stopping treatment,” said Mohamed Zaki , M.D., NORTH CHICAGO, Ill. 0.45]); results are descriptive.

Treatment 40

Treatment Trials Therapies Clinical Trials 40

The Pharma Data

OCTOBER 25, 2020

Food and Drug Administration (“FDA”) for the treatment of agitation associated with delirium. Treatment choices are limited, and commonly used off-label therapies are not always effective or may result in prolonged, deep sedation. This condition may be caused by numerous underlying pathologic processes and disease states.

Treatment 52

Treatment Trials FDA Hospitals 52

The Pharma Data

NOVEMBER 4, 2020

New data will also be presented that show the safety and efficacy of ULTOMIRIS when used concomitantly with immunosuppressive therapy (IST) in patients with PNH. aHUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots.

Doctors 52

Doctors Vaccine Nurses Treatment 52

The Pharma Data

JANUARY 27, 2021

The report entitled “Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women” was written by nurse practitioner Melissa Fesler and internist Raphael Stricker from the Alan E. This antimicrobial agent was originally promoted for treatment of severe SARS-CoV-2 infection using high daily doses in combination with other medications.

Vaccine 52

Vaccine Nurses International Treatment 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops.

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

DECEMBER 17, 2020

These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention,” said George D. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 20, 2020

20, 2020 (American Heart Association News) — Heart disease and depression are interwoven, and a new study is helping unravel that connection by linking depression with poorer scores on seven important measures of heart health. People with depression are more likely to develop heart disease. FRIDAY, Nov. That is “critical.

Nurses 52

Nurses Disease Research Hospitals 52

The Pharma Data

JANUARY 12, 2021

Patients, caregivers and healthcare providers can find sites with COVID-19 antibody treatments through these links to the HHS or National Infusion Center Association locator tools. . Regeneron is responsible for development and distribution of the treatment in the U.S. , who require oxygen therapy due to COVID-19, OR.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. The benefit was driven by results starting one week post-treatment, when the risk of death or receiving mechanical ventilation was reduced by approximately half with antibody cocktail treatment, based on a post-hoc analysis.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

FEBRUARY 8, 2021

IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy.

Clinical Trials 52

Clinical Trials Treatment Therapies Production 52

The Pharma Data

FEBRUARY 1, 2021

1, 2021 — As America’s vaccination campaign begins to gain momentum, a promising sign has emerged: Federal data shows that coronavirus cases in nursing homes have declined over the past four weeks. The country recorded 17,584 cases in nursing homes during the week ending Jan. Centers for Disease Control and Prevention.

Nurses 52

Nurses Vaccine Long-Term Care Facilities Virus 52

PLOS: DNA Science

JUNE 1, 2023

The newest FDA-approved gene therapy treats the severe, skin-peeling condition dystrophic epidermolysis bullosa (DEB). The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done. DEB has been a candidate for a gene therapy since 2002.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

The Pharma Data

MAY 27, 2022

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response . In December 2017, Janssen Biotech, Inc. to develop and commercialise cilta-cel.[1].

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

The Pharma Data

NOVEMBER 20, 2020

(NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Schleifer, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

APRIL 8, 2021

OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs). Following U.S.

Clinical Trials 52

Clinical Trials Trials Disease Nurses 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. INDIANAPOLIS, Jan. have reached record highs. .

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

JUNE 18, 2021

. “We are encouraged by these promising results, which indicate ibrutinib and venetoclax combined has the potential to serve as an important chemotherapy-free, fixed-duration treatment option for people living with CLL,” said Dr. Paolo Ghia , M.D., 95% irrespective of subsequent randomized treatment ( Wierda, ASH 2020 ).

Treatment 40

Treatment FDA FDA Approval Therapies 40

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

APRIL 28, 2023

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Teva Pharmaceuticals, a U.S. We are committed to supporting patients through innovative therapy options.

FDA Approval 40

FDA Approval Treatment FDA Clinical Trials 40

Altus Drug Development

MAY 31, 2022

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. What is a value-added medicine?

Treatment 52

Treatment Pharmaceuticals Production Doctors 52

The Pharma Data

NOVEMBER 21, 2020

21, 2020 /PRNewswire/ — First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2. TARRYTOWN, N.Y. , Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients. government allocation program. Food and Drug Administration (FDA).

FDA 40

FDA Clinical Trials Hospitals Government 40

Agency IQ

JULY 12, 2024

Intended use includes such things as the condition or disease which the product is meant to treat, the population for whom it is intended, and the route, frequency of administration, and duration of use for the product.

FDA 40

FDA Regulations Production Science 40

The Pharma Data

AUGUST 11, 2020

Responses to the current standard chemotherapy in patients are short lived, and less than 6% of patients with metastatic disease survive beyond five years,” said Yelena Y. We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.”.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. This single dose infusion-based treatment is provided on an outpatient basis and marks a dramatic shift in COVID-19 care. Currently receiving immunosuppressive treatment.

Hospitals 40

Hospitals Treatment Virus Nurses 40

The Pharma Data

DECEMBER 1, 2020

13 to 17 and attracted participants from around the world, including cardiovascular specialists, surgeons, and nurses as well as other health care professionals. The researchers found that increased greenness and air quality reduced cardiovascular disease mortality. In a cross-sectional study, William Aitken, M.D., born Black women.

Hospitals 52

Hospitals Disease Treatment Nurses 52

The Pharma Data

APRIL 28, 2021

The positive CHMP opinion is a scientific recommendation for marketing authorization to the European Commission (EC), which is expected to deliver its final decision on VENCLYXTO combination therapy for use in AML in the first half of 2021. . 1 An estimated 160,000 people are currently living with the disease globally.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. and 17.1%, respectively.

Treatment 52

Treatment Therapies FDA FDA Approval 52

The Pharma Data

JUNE 18, 2021

May 25, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Clinical Trials 40

Clinical Trials Treatment Trials Therapies 40

The Pharma Data

DECEMBER 3, 2020

The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. BEDFORD, Mass.–( –( BUSINESS WIRE )– Stoke Therapeutics , Inc. Chief Medical Officer of Stoke Therapeutics. Devices, Technologies, Stem Cells.

Protein Expression 52

Protein Expression Clinical Trials Pharmacokinetics Trials 52

The Pharma Data

JANUARY 24, 2021

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. Non-COVID-19-Related.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

JULY 23, 2021

Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. “This pediatric approval for DALVANCE as a single-dose provides a meaningful contribution to the treatment of children and infants with ABSSSI.”

FDA Approval 52

FDA Approval FDA Clinical Trials Trials 52

The Pharma Data

AUGUST 3, 2021

Food & Drug Administration (FDA) for Istodax ® (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. Bristol Myers Squibb is notifying healthcare professionals about the withdrawal. About Istodax.

Nurses 52

Nurses Clinical Trials Treatment Laboratories 52

The Pharma Data

NOVEMBER 17, 2020

She speaks nationally and internationally on how cancer and autoimmune disease therapies affect reproductive health and fertility, ovarian aging, primary ovarian insufficiency and genetics. Hammond , DNP, CRNP is a board-certified Nurse Practitioner, is IVF Program Director at AIRM. Karen R. Karen R.

Laboratories 52

Laboratories Nurses Doctors International 52

The Pharma Data

MAY 13, 2021

I could hear doctors and nurses speaking in hushed tones…. And Mary-Anne, a nurse from Arkansas, who says…. I’d always assumed that Jen just did estrogen replacement therapy or something like that…. Estrogen therapy is expensive and scary as heck. Or risky estrogen therapies…. And the energy, my god. Jenn told me.

Production 52

Production Packaging Doctors Research 52

The Pharma Data

MAY 13, 2021

Heart disease. While not quite a universal treatment for cancer, this little island has its fair share of miracle stories. All around you, heart disease is skyrocketing. I developed heart disease in my 40s. Me, a former fat guy with crippling heart disease. Optimism for your future. Just getting fatter and sicker.

Doctors 52

Doctors Production Research Science 52